NCT05767879 - (Neo)Adjuvant BRAF/MEK Inhibition in pN1c Melanoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 1, 2022

Primary Completion Date

January 1, 2026

Study Completion Date

January 1, 2026

Conditions

Melanoma Stage IIIIn-Transit Metastasis of Cutaneous Melanoma

Interventions

DRUG

Encorafenib + Binimetinib

"In the open label phase II study, the combination of BRAF/MEK inhibition with encorafenib/binimetinib in the neo-adjuvant setting will be investigated.~Furthermore, efficacy of adjuvant BRAF/MEK inhibition with encorafenib/binimetinib, for 44 weeks will be evaluated."

Trial Locations (1)

2311GP

RECRUITING

Leiden University Medical Center, Leiden